Development of Regulatory T Cells (Tregs) Based Therapy for Autoimmune Diseases

The successful outcome of first regulatory T cells (Tregs) based cellular therapies leads to an increasing number of clinical trials using Tregs, and the area of interest can be pointed to autoimmune disorders (AD). With abundant expertise in autoimmune disorders research, Creative Biolabs offers development services for Tregs based therapy to help the research of autoimmune diseases.

Introduction of Regulatory T Cells (Tregs)

Tregs are a subset of the cluster of differentiation 4 receptors (CD4)+ T lymphocytes that possess the capacity to suppress immune responses. Tregs are broadly grouped into two categories, either natural (thymus-derived) or induced (peripherally derived) cells. Natural Tregs (nTregs) represent 2~8% of CD4+ T cells in healthy donor peripheral blood. Induced Tregs can be generated by the expansion of CD4+ T cells in the presence of transforming growth factor-β (TGFβ). The importance of Tregs in immune regulation and brokering tolerance has been robustly demonstrated. Expanded polyclonal Tregs are being developed for clinical applications.

Fig.1 New therapeutic approaches for autoimmune disease. (Peter, 2020)

Preparation of Antigen-Specific Tregs for Autoimmune Diseases Therapy

Treg therapy can be enhanced by the introduction of an autoantigen-specific T-cell receptor (TCR-Treg). Tregs can be ex vivo-transduced, by the way of retroviral or lentiviral transduction, to express a high-affinity, autoantigen-specific TCR. Tregs can be subsequently expanded for use as a cell-based therapy to treat a specific autoimmune disease.

Creative Biolabs offers one-stop preparation services of antigen-specific Tregs to promote the research and therapy development of autoimmune diseases. Our common protocols are optimized for Treg isolation and the purity of isolated Treg is up to 98%. Separate services or integrated end-to-end solutions are all welcomed.

Chimeric Autoantibody Receptor (CAAR)-Engineered Tregs for Autoimmune Diseases Therapy

Creative Biolabs has rich experience in the identification, isolation, and functional assay of Tregs. Moreover, we have explored a great variety of creative autoantibody receptor (CAAR)-engineered Tregs that have already been designed and shown to be effective in models of autoimmune disease. We are confident in providing you with the best CAAR-engineered Tregs development services to advance your non-clinical research of Tregs-based therapy in the field of autoimmune diseases.

Fig.2 Mechanisms of action in Treg therapy. (Peter, 2020)

Validation of Treg-Based Therapy for Autoimmune Diseases

High-purity Treg is needed for further research. Treg has a variety of cell phenotypes. Therefore, it is necessary to screen T cells with high purity and high activity. Although the technology of cell culture is relatively mature, there are still a lot of "traps" that you need to pay special attention to. Creative Biolabs provides Treg validation services to ensure purity, function, and identification.

With abundant expertise in autoimmune disorders research, Creative Biolabs offers one-stop development services for Tregs based therapy to help the research of autoimmune diseases. If you are interested in Treg-based therapy development services for autoimmune disease, you can contact us.

Reference

1. Peter, J. Eggenhuizen. Treg Enhancing Therapies to Treat Autoimmune Diseases. International Journal of Molecular Sciences. 2020.

For Research Use Only | Not For Clinical Use